Comparative Pharmacology
Head-to-head clinical analysis: ASHLYNA versus HALOETTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASHLYNA versus HALOETTE.
ASHLYNA vs HALOETTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASHLYNA is a combination of ethinyl estradiol and drospirenone. The contraceptive effect is based on inhibition of ovulation and alterations in cervical mucus and endometrial receptivity. Drospirenone has antimineralocorticoid and antiandrogenic activity.
Etonogestrel is a progestin that suppresses gonadotropin release, inhibiting ovulation and increasing cervical mucus viscosity.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 placebo tablets.
One 13.9 mg subcutaneous etonogestrel implant inserted into the inner side of the non-dominant upper arm for contraception; effective for 3 years.
None Documented
None Documented
Terminal half-life: 12–15 hours; clinical context: supports once-daily dosing
Terminal elimination half-life is approximately 1.3–1.7 hours (mean 1.5 hours). The short half-life supports continuous intravenous infusion for sustained sedation in critical care.
Renal: ~60% unchanged; fecal: ~30% (metabolites); biliary: ~10%
Renal excretion of metabolites accounts for approximately 85–90% of elimination; biliary/fecal excretion accounts for 10–15%.
Category C
Category C
Contraceptive
Contraceptive